EX-10.1 2 d541282dex101.htm EX-10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under Execution Version Amended and Restated Ex-US Commercialization Agreement This Amended and...Ex-Us Commercialization Agreement • May 5th, 2020 • New York
betweenex-u.s. Commercialization Agreement • March 12th, 2004 • Genta Inc De/ • Biological products, (no disgnostic substances) • New York
Ex-US Commercialization AgreementEx-Us Commercialization Agreement • May 2nd, 2018 • Foundation Medicine, Inc. • Services-medical laboratories • New York
WHEREAS, FMI has certain products that it currently commercializes, and additional products that it would like to commercialize in the future, either by itself or through a collaborator;
SECOND AMENDMENT TO EX-US COMMERCIALIZATION AGREEMENTEx-Us Commercialization Agreement • March 7th, 2018 • Foundation Medicine, Inc. • Services-medical laboratories • New York
This Second Amendment to Ex-US Commercialization Agreement (“Second Amendment”), effective as of October 10, 2017 (“Second Amendment Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland (“Roche”) and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. (“FMI”) (each a “Party,” and collectively, the “Parties”), and amends that certain Ex-US Commercialization Agreement, by and between the Parties, effective as of April 7, 2015, as amended by the First Amendment to Ex-US Commercialization Agreement, effective as of May 9, 2016 (collectively, the “Agreement”). Capitalized terms used in this Second Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.
Ex-US Commercialization AgreementEx-Us Commercialization Agreement • August 24th, 2015 • Foundation Medicine, Inc. • Services-medical laboratories • New York
WHEREAS, FMI has certain products that it currently commercializes, FoundationOne® and FoundationOne® Heme, and would like to commercialize, either by itself or through a collaborator, additional products in the future; and
FIRST AMENDMENT TO EX-US COMMERCIALIZATION AGREEMENTEx-Us Commercialization Agreement • August 3rd, 2016 • Foundation Medicine, Inc. • Services-medical laboratories
This First Amendment (“First Amendment”) to the Ex-US Commercialization Agreement (the “Agreement”), effective April 7, 2015, by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland ( “Roche”), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. (“FMI”), on the other hand (each a “Party,” and collectively, the “Parties”), is entered into by and between the Parties on May 9, 2016 and shall be considered effective as of April 7, 2016 (the “First Amendment Effective Date”). Capitalized terms used in this First Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.
Ex-US Commercialization AgreementEx-Us Commercialization Agreement • February 2nd, 2015 • Foundation Medicine, Inc. • Services-medical laboratories • New York
WHEREAS, FMI has certain products that it currently commercializes, FoundationOne® and FoundationOne® Heme, and would like to commercialize, either by itself or through a collaborator, additional products in the future; and
THIRD AMENDMENT TO EX-US COMMERCIALIZATION AGREEMENTEx-Us Commercialization Agreement • March 7th, 2018 • Foundation Medicine, Inc. • Services-medical laboratories • New York
This Third Amendment to Ex-US Commercialization Agreement (“Third Amendment”), is entered into as of December 8, 2017 (“Third Amendment Execution Date”) and shall be effective as of December 1, 2017, by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland (“Roche”) and Foundation Medicine, Inc., with an office and place of business at 150 Second Street, Cambridge, MA 02141, U.S.A. (“FMI”) (each a “Party,” and collectively, the “Parties”), and amends that certain Ex-US Commercialization Agreement, by and between the Parties, effective as of April 7, 2015, as amended by the First Amendment to Ex-US Commercialization Agreement, effective as of May 9, 2016 and the Second Amendment to Ex-US Commercialization agreement, effective as of October 17, 2017 (collectively, the “Agreement”). Capitalized terms used in this Third Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreem
